Skip to content

Committee Composition

Board of Directors Audit & Finance Leadership & Compensation Nominating & Corporate Governance Quality Compliance Science & Innovation Strategy & Risk
David R. Brennan
Chairman
David R. Brennan is Chairman of Alexion’s Board of Directors. He served as a Director of Alexion since July 2014 and as Interim Chief Executive Officer of Alexion from December 2016 to March 2017. 
 
From 2006 to 2012, he served as Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world's largest pharmaceutical companies. Mr. Brennan worked for AstraZeneca in increasing roles of responsibility, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. 
 
Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career in 1975 at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck.
 
Mr. Brennan currently serves on the Board of Directors of Innocoll, Inc. and Insmed Incorporated, and previously served on the Board of Directors of AstraZeneca PLC, Reed Elsevier PLC, and the Pharmaceutical Research & Manufacturers of America (PhRMA).
 
Mr. Brennan received a BA in business administration from Gettysburg College, where he is a member of the Board of Trustees.
 
Mr. Brennan is a member of the Strategy and Risk Committee, the Quality Compliance Committee, and the Science and Innovation Committee.
     
Felix J. Baker Ph.D.
Director

Felix J. Baker, Ph.D. has been a director of Alexion since June 2015. Dr. Baker is a Co-Managing Member of Baker Bros. Advisors LP, an investment advisor focused on investments in life science and biotechnology companies.  Dr. Baker and his brother, Julian Baker, started their fund-management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker currently serves on the Board of Directors at Genomic Health, Inc. and Seattle Genetics, Inc. and previously served on the Board of Directors at Synageva BioPharma Corp. and Ardea Bioscience, Inc. 

Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

Dr. Baker is Chair of the Science and Innovation Committee and a member of the Quality Compliance Committee and the Strategy and Risk Committee.

     
M. Michele Burns
Director

M. Michele Burns has been a director of Alexion since July 2014. She currently serves as Center Fellow and Strategic Advisor, Stanford University Center on Longevity. She served in senior executive roles with Marsh & McLennan Companies, Inc. ("MMC"), including as Chief Executive Officer, Retirement Policy Center sponsored by MMC from 2012 to 2014, Chairwoman and Chief Executive Officer of Mercer LLC, a subsidiary of MMC, from 2006 to 2011, and Executive Vice President and Chief Financial Officer of MMC in 2006. From 2004 to 2006, Ms. Burns served as Executive Vice President, Chief Financial and Chief Restructuring Officer for Mirant Corporation. From 1999 to 2004 she worked in increasing roles of responsibility at Delta Air Lines, serving as Executive Vice President and Chief Financial Officer of Delta from 2000 to 2004. Ms. Burns began her career with Arthur Andersen, and over an 18-year tenure rose to Senior Partner, leading Andersen's Southern Region Federal Tax Practice, heading its U.S. Healthcare Tax Practice and its Southeastern Region Financial Services Tax Practice, and serving on its Global Advisory Council. Ms. Burns currently serves on the Board of Directors of AB InBev, Etsy, The Goldman Sachs Group, Inc., and Cisco Systems, Inc., and private company Circle Internet Financial, Ltd. She also serves as Treasurer of the Elton John Aids Foundation. She previously served on the Board of Directors of Wal-Mart Stores, Inc., Ivan Allen Company, and Orbitz, LLC.

Ms. Burns received a BA in business administration and a Master of Accountancy from the University of Georgia.

Ms. Burns is Chair of the Strategy and Risk Committee and a member of the Leadership and Compensation Committee and the Nominating and Corporate Governance Committee.

     
Christopher J. Coughlin
Director

Christopher J. Coughlin has been a director of Alexion since July 2014. He served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010 and during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to 1998 he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin currently serves on the Board of Directors of Allergan plc. He previously served on the Board of Directors of Covidien (acquired by Medtronic), Actavis (which acquired Allergan), Dun & Bradstreet, Forest Laboratories (acquired by Actavis plc), Hologic, Inc., Dipexium Pharmaceuticals, Inc., The Interpublic Group of Companies, Monsanto Company, and Perrigo Company.

Mr. Coughlin received a BS in accounting from Boston College.

Mr. Coughlin is Chair of the Audit and Finance Committee and a member of the Quality Compliance Committee and the Nominating and Corporate Governance Committee.

     
John T. Mollen
Director

John T. Mollen has been a director of Alexion since April 2014. Mr. Mollen served as Executive Vice President, Human Resources (HR) of EMC Corporation from May 2006 until his retirement in February 2014, including two years as special advisor to the President. He joined EMC as Senior Vice President, Human Resources in September 1999. While at EMC, Mr. Mollen led the global human resources function to ensure the availability of world-class talent to drive business success and his responsibilities included executive, leadership, and employee development; compensation and benefits; staffing; and all of the people-related aspects of acquisition integration. Prior to joining EMC, Mr. Mollen was Vice President of Human Resources at Citigroup Inc. Mr. Mollen serves as a director for a number of not-for-profit and professional boards, including the New England Healthcare Institute, the HR Policy Association, Center on Executive Compensation, and as an advisory board member for Working Mother magazine and he is Chairman of the Board of Trustees of Worcester Polytechnic Institute.

Mr. Mollen received a bachelor's degree in economics from St. John Fisher College in Rochester, N.Y., and a master's degree in labor relations from St. Francis University in Loretto, Pa.

Mr. Mollen is Chair of the Leadership and Compensation Committee and a member of the Audit and Finance Committee and the Nominating and Corporate Governance Committee.

     
R. Douglas Norby
Lead Independent Director

R. Douglas Norby has been a director of Alexion since September 1999 and was appointed lead independent director in October 2014. In addition to serving on Alexion’s Board, he has held positions of increasing responsibility at many companies, including serving as Senior Vice President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging, and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks, as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company, as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company, and as President and Chief Operating Officer at Lucasfilm, Ltd., an entertainment company. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, and as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company.

Mr. Norby received a B.A. in Economics from Harvard University and an M.B.A. from Harvard Business School.

Mr. Norby is a member of the Audit and Finance Committee, the Leadership and Compensation Committee and the Nominating and Corporate Governance Committee.

     
Alvin S. Parven
Director

Alvin S. Parven has been a director of Alexion since May 1999. He has been President of ASP Associates, a management and strategic consulting firm, since 1997. Prior to that, Mr. Parven held positions of increasing responsibility within the Aetna family of companies, serving as Vice President at Aetna Business Consulting, Vice President, Operations at Aetna Health Plans and Vice President, Pension Services. Mr. Parven is a trustee of the Employee Retirement Board of the Town of Palm Beach and a director of the Palm Beach Civic Association.

Mr. Parven received a B.A. from Northeastern University.

Mr. Parven is a member of the Audit and Finance Committee, the Leadership and Compensation Committee and the Nominating and Corporate Governance Committee.

     
Andreas Rummelt, Ph.D.
Director
Dr. Andreas Rummelt has been a director of Alexion since February 2010. He has held executive management positions internationally for more than 20 years in the pharmaceutical industry, focused in the areas of manufacturing, quality and technical matters. He is currently the CEO and Partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis, and served as a member of the Executive Committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, Head of Technical Operations of the Novartis Pharmaceuticals Division. 
 
Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He received executive training in general management and leadership from IMD in Lausanne (Switzerland), INSEAD in Fontainebleau (France), and Harvard Business School in Cambridge (USA).
 
Dr. Rummelt is Chair of the Quality Compliance Committee and a member of the Science and Innovation Committee and the Strategy and Risk Committee.
     
Ann M. Veneman J.D.
Director

Ann M. Veneman, J.D. has been a director of Alexion since May 2010. Prior to this, she has served as Executive Director of the United Nations Children's Fund (UNICEF), leading a global organization which supports multiple aspects of child health, nutrition, safety and education. Ms. Veneman was responsible for more than 11,000 staff members in more than 150 countries. Before joining UNICEF, Ms. Veneman was the first woman to serve as Secretary of the U.S. Department of Agriculture (USDA), leading an organization of 110,000 employees with an annual budget of $113 billion. She has also worked as California’s Secretary of Food and Agriculture. An attorney by training, she has practised law in Washington, D.C. and California in both the private and public sectors. Ms. Veneman serves on the not-for-profit boards of the Global Health Innovative Technology Fund and Just Capital and serves on the Board of Directors at Nestle, S.A.

Ms. Veneman earned a Bachelor's degree in political science from the University of California, Davis; a Master's degree in public policy from the University of California, Berkeley; and a Juris Doctorate from the University of California, Hastings College of Law.

Ms. Veneman is Chair of the Nominating and Corporate Governance Committee and a member of the Quality Compliance Committee and the Strategy and Risk Committee.
     
= Chair of the Board
= Chair
= Member
= Lead Independent Director